Header

UZH-Logo

Maintenance Infos

Scalp psoriasis: European consensus on grading and treatment algorithm


Ortonne, J; Chimenti, S; Luger, T; Puig, L; Reid, F; Trüeb, R M (2009). Scalp psoriasis: European consensus on grading and treatment algorithm. Journal of the European Academy of Dermatology and Venereology, 23(12):1435- 1444.

Abstract

The scalp is a common site of involvement of psoriasis and, for many patients, is a challenging aspect of their disease. This can be attributed not only to the scaling, itching and cosmetic embarrassment that go with scalp psoriasis, but also to the fact that the scalp skin is relatively inaccessible, making topical therapies difficult to apply. The proximity of sensitive facial skin can also limit the use of potentially irritating topical treatments. Nevertheless, the specific challenges of scalp psoriasis are often neglected by treatment guidelines. This paper summarizes the discussions that took place at an international conference of experts convened in Geneva, Switzerland, in March 2008. The objective of the meeting was to review the available treatments for scalp psoriasis in terms of efficacy, safety, convenience, and the implications for patient compliance with treatment. In addition, definitions of mild, moderate and severe scalp psoriasis were agreed. This paper presents a treatment algorithm that includes recommendations for patients in all three categories. It considers the role of potent topical corticosteroids, vitamin D3 derivatives, salicylic acid preparations, and photo- and radiotherapy, as well as systemic therapies, including newer biological agents, for patients with widespread psoriasis with scalp involvement. Data from clinical trials indicate that a potent topical corticosteroid in a short-contact formulation is the most appropriate treatment for most patients with scalp psoriasis. Conflicts of interest The consensus meeting of European experts on management of scalp psoriasis has been organized by LEO Pharmaceuticals. J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. J.P. Ortonne is also a paid consultant for Galderma. Lluís Puig has participated as Principal Investigator in a clinical trial sponsored by Galderma. Galderma has provided funding to support the work in this project.

Abstract

The scalp is a common site of involvement of psoriasis and, for many patients, is a challenging aspect of their disease. This can be attributed not only to the scaling, itching and cosmetic embarrassment that go with scalp psoriasis, but also to the fact that the scalp skin is relatively inaccessible, making topical therapies difficult to apply. The proximity of sensitive facial skin can also limit the use of potentially irritating topical treatments. Nevertheless, the specific challenges of scalp psoriasis are often neglected by treatment guidelines. This paper summarizes the discussions that took place at an international conference of experts convened in Geneva, Switzerland, in March 2008. The objective of the meeting was to review the available treatments for scalp psoriasis in terms of efficacy, safety, convenience, and the implications for patient compliance with treatment. In addition, definitions of mild, moderate and severe scalp psoriasis were agreed. This paper presents a treatment algorithm that includes recommendations for patients in all three categories. It considers the role of potent topical corticosteroids, vitamin D3 derivatives, salicylic acid preparations, and photo- and radiotherapy, as well as systemic therapies, including newer biological agents, for patients with widespread psoriasis with scalp involvement. Data from clinical trials indicate that a potent topical corticosteroid in a short-contact formulation is the most appropriate treatment for most patients with scalp psoriasis. Conflicts of interest The consensus meeting of European experts on management of scalp psoriasis has been organized by LEO Pharmaceuticals. J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. J.P. Ortonne is also a paid consultant for Galderma. Lluís Puig has participated as Principal Investigator in a clinical trial sponsored by Galderma. Galderma has provided funding to support the work in this project.

Statistics

Citations

Dimensions.ai Metrics
31 citations in Web of Science®
29 citations in Scopus®
36 citations in Microsoft Academic
Google Scholar™

Altmetrics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2009
Deposited On:17 Mar 2010 14:16
Last Modified:18 Feb 2018 00:14
Publisher:Wiley-Blackwell
ISSN:0926-9959
OA Status:Closed
Publisher DOI:https://doi.org/10.1111/j.1468-3083.2009.03372.x
PubMed ID:19614856

Download

Full text not available from this repository.
View at publisher